Sculptra (poly-L-lactic acid) as of August 2004 has been approved by the U.S. Food and Drug Administration as the first injectable facial volumizer in the treatment of lipoatrophy. Lipoatrophy is often seen in HIV-positive patients and is felt to be multifactorial. This article reviews European and U.S. clinical study data and summarize treatment technique for both on label and off-label use.
